502687-90-3

Basic information

• Product Name: (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α,25-diol
• Synonyms: (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α,25-diol
• CAS NO: 502687-90-3
• Molecular Weight: 661.169
• Mol File: 502687-90-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α,25-diol(CAS DataBase Reference)
• NIST Chemistry Reference: (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α,25-diol(502687-90-3)
• EPA Substance Registry System: (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-16α,25-diol(502687-90-3)

Safety Data

• Hazardous Substances Data: 502687-90-3(Hazardous Substances Data)

Upstream product

• 502687-95-8 (20S)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]cholestan-25-ol-16α-yl acetate 
• 502687-85-6 (20S)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]-25-[(trimethylsilyl)oxy]cholest-16-ene 
• 502687-84-5 (20S)-des-A,B-8β-[(tert-butyldimethylsilyl)oxy]cholestane-16α,25-diol 
• 502687-88-9 (20S)-des-A,B-25-[(trimethylsilyl)oxy]cholestan-8-on-16α-yl acetate 
• 502687-87-8 (20S)-des-A,B-cholestane-8β,25-diol-16α-yl acetate 
• 502687-96-9 (20S)-des-A,B-25-hydroxycholestan-8-on-16α-yl acetate 
• 67883-17-4 1-bromo-3-methyl-3-trimethyl-silyloxybutane 
• 502687-89-0 (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-25-ol-16α-yl acetate 

Downstream Products

• 502687-91-4 (5Z,7E)-(1R,3S,20S)-1,3-bis[(tert-butyldimethylsilyl)oxy]-9,10-secocholesta-5,7,10(19)-trien-25-ol-16α-yl hydrogen glutarate 

Relevant articles and documents

Synthesis of novel hapten derivatives of 1α,25-dihydroxyvitamin D3 and its 20-epi analogue

Hapten derivatives of 1α,25-dihydroxyvitamin D3 and its 20-epimer were synthesized and conjugated to a carrier protein for raising polyclonal antibodies. The haptens were linked through spacers at C-16, thereby exposing both the A-ring and the side chain of the molecules, to maximize antibody specificity. The spacers were introduced via stereoselective hydroboration of 16-ene intermediates as the key step. In immunoassays, the antibodies raised toward the natural hormone were selective to this compound over derivatives with modifications in the A-ring or the side chain. The antibodies toward the 20-epimer, however, were unable to recognize modifications in the side chain.